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ABSTRACT
Systemic sclerosis (SSc), or sclero-
derma, is a chronic multisystem au-
toimmune disorder characterised by 
thickening and ﬁbrosis of the skin and 
by the involvement of internal organs 
such as the lungs, kidneys, gastrointes-
tinal tract, and heart. Because there is 
no cure, feasibly-implemented and eas-
ily accessible evidence-based interven-
tions to improve health-related quality 
of life (HRQoL) are needed. Due to a 
lack of evidence, however, speciﬁc rec-
ommendations have not been made 
regarding non-pharmacological inter-
ventions (e.g. behavioural/psychologi-
cal, educational, physical/occupational 
therapy) to improve HRQoL in SSc. The 
Scleroderma Patient-centred Interven-
tion Network (SPIN) was recently or-
ganised to address this gap. SPIN is 
comprised of patient representatives, 
clinicians, and researchers from Can-
ada, the USA, and Europe. The goal 
of SPIN, as described in this article, is 
to develop, test, and disseminate a set 
of accessible interventions designed to 
complement standard care in order to 
improve HRQoL outcomes in SSc.
Introduction
More than 25 million people in North 
America and more than 30 million in 
Europe are affected by a rare disease, 
deﬁned in the United States as a condi-
tion with fewer than 7 prevalent cases 
per 10,000 people and by the European 
Union as fewer than 5 prevalent cases 
per 10,000 (1). Patients with rare dis-
eases face many challenges, perhaps 
foremost among these, the lack of rigor-
ously tested interventions and evidence-
based care standards to direct patient 
care (2, 3). Indeed, the complexities 
involved in ensuring that patients with 
rare diseases have access to effective 
drugs is well documented (1). Beyond 
drug therapies, organisations that rep-
resent patients with rare diseases often 
have a clear idea of what kind of dis-
ease-speciﬁc supportive care is needed 
and how it might be provided, but these 
ideas are rarely translated into acces-
sible, evidence-based, patient-centred 
care programmes (2). 
In order to develop an evidence-based 
patient-centred care programme for 
patients with a rare disease, an active 
partnership among researchers, health 
care providers, and patients is necessary 
(4, 5). Furthermore, effective research 
in rare diseases requires successful 
multicentre collaborations. The NIH, 
for instance, created the Rare Diseases 
Clinical Research Network to support 
research on rare diseases. In systemic 
sclerosis (SSc), or scleroderma, there 
are several examples of ongoing col-
laborative efforts. The international 
Scleroderma Clinical Trials Consortium 
conducts multicentre drug trials. There 
are national SSc registries in the UK, 
Germany, USA, Brazil, Australia, and 
Canada, and there is an international 
registry, established by the European 
League Against Rheumatism Sclero-
derma Trial and Research (EUSTAR), 
which consists of minimal essential 
data from over 8,000 patients across 
92 centres (6). None of these, however, 
focuses on developing evidence-based 
patient-centred care interventions.
SSc is characterised clinically by thick-
ening and ﬁbrosis of the skin and by the 
involvement of internal organs, most 
commonly the lungs, gastrointestinal 
tract and heart (7, 8). Prevalence esti-
mates vary from less than 0.1 to 4.9 cas-
es per 10,000 (9) with the disease at least 
4 times more prevalent in women than 
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men (10). The pathogenesis and etiology 
of SSc are complex and not completely 
understood. However, vascular damage, 
immunological/inﬂammatory system 
activation, and excessive collagen pro-
duction are known to be important in the 
development of the disease (11). Median 
survival time from diagnosis is approxi-
mately 11 years, and patients are 3.7 
times more likely to die within 10 years 
of diagnosis (44.9% mortality) than 
age, sex, and race-matched individuals 
without SSc (12.0% mortality) (12). The 
effects of SSc often result in signiﬁcant 
disruptions to activities of daily living 
and can negatively affect quality of life, 
including physical and psychological 
well-being (13, 14). While treatments 
for some of the manifestations of the 
disease are available, there are no cures 
or true disease modifying agents for 
a majority of SSc complications (15). 
Given this, there is an urgent need for 
interventions to improve HRQoL. 
Despite the marked physical, medical, 
and functional changes experienced by 
persons with SSc, HRQoL has received 
relatively little attention in SSc com-
pared to other rheumatic diseases. Clin-
ical trial data related to behavioural/
psychological, educational, and physi-
cal/occupational therapy interventions 
are lacking, and the most recent man-
agement guidelines for SSc (15) were 
not able to make recommendations for 
or against these types of interventions. 
Nonetheless, a number of key problems 
have been identiﬁed that contribute to 
HRQoL for many people with SSc and 
are potentially amenable to interven-
tions with non-pharmacological, ad-
junctive health care strategies. 
Common problems in SSc 
potentially addressed by adjunctive 
health care interventions
SSc is notable for the many different 
problems faced by people living with 
the disease. A number of these prob-
lems have been reported by patients 
to signiﬁcantly inﬂuence health and 
well-being, including limitations in 
physical mobility; pain; fatigue; sleep 
disturbance; psychological distress in-
cluding depression and anxiety; sexual 
dysfunction; and body image distress 
(13, 14, 16-18).
Physical mobility/hand function
SSc results in a range of physical limi-
tations, including difﬁculty with eating 
and speaking, reductions in exercise 
tolerance and muscle strength, and 
impaired hand function. Contractures 
and deformities of the hand, consist-
ing of decreased ﬂexion and limited 
extension as well as reduced thumb 
abduction, are common among peo-
ple with SSc (19), and limited hand 
function is an important contributor to 
overall disability and reduced HRQoL 
(20, 21). A recent Canadian national 
survey (n=464) found that more than 
two-thirds of SSc patients reported 
experiencing hand stiffness, difﬁculty 
making a ﬁst, or difﬁculty holding ob-
jects that impacted daily activities at 
least some of the time (16). Problems 
related to hand function were among 
the top in both frequency and impact, 
among the 69 symptoms/problems in 
the survey checklist. Not surprising-
ly, another recent study reported that 
89% of the SSc patients sampled had 
problems with hand function, as skin 
and tendon involvement of the hands 
is nearly universal in SSc (22). There 
have been 3 randomised controlled tri-
als (RCTs) of physical or occupational 
therapy interventions to improve hand 
function in SSc, but none has included 
more than 20 patients per treatment 
or control groups (23). Recently, Sch-
ouffoer et al. (24) reported that a 12-
week multidisciplinary day patient 
treatment programme that included a 
physical therapy component yielded 
greater improvements in grip strength 
and on the Scleroderma Health As-
sessment Questionnaire (SHAQ) for 
28 patients who received the interven-
tion, compared to 25 patients who re-
ceived usual care.
Pain
Pain levels in SSc are similar to those 
reported in other chronic pain and rheu-
matic conditions (25-27). Between 60–
83% of SSc patients experience pain 
(25, 28), and it is a signiﬁcant source 
of distress, reduced physical and social 
functioning, and disability for many 
people living with the disease (13, 25, 
28). Pain in SSc may have numerous 
sources, including skin pain; pain as-
sociated with Raynaud’s phenomenon; 
musculoskeletal pain; pain in distal ex-
tremities due to tightness, calcinosis, 
and ulcers; gastrointestinal problems, 
as well as depressive symptoms (13, 
14, 25, 29).
Fatigue
Levels of fatigue in SSc are similar to 
those reported by patients with other 
rheumatic diseases and cancer patients 
undergoing treatment, and higher than 
in the general population or among 
cancer patients in remission (30). Al-
most 90% of patients who responded 
to a Canadian survey (n=464) said that 
fatigue was present at least some of the 
time, and 72% said that fatigue had a 
moderate to severe impact on their 
ability to carry out daily activities (16). 
A Dutch study found that fatigue was 
present in 75% of 123 SSc patients and 
was reported as one of the most both-
ersome symptoms associated with the 
disease (31). Numerous studies have 
shown that fatigue in SSc is associat-
ed with the inability to carry out daily 
activities, work disability, and limited 
overall physical functioning, even af-
ter controlling for potential confound-
ing variables such as education level, 
disease subtype, pain, sleep quality, 
and depressive symptoms (32-34). A 
number of medical comorbidities are 
associated with fatigue in SSc, includ-
ing breathing and gastrointestinal prob-
lems, pain, and depression (35).
Sleep disturbance
Recent ﬁndings indicate that patients 
with SSc report marked sleep distur-
bance. One study found that compared 
to the US general population, patients 
with SSc reported signiﬁcantly worse 
sleep quality and this poor sleep was 
associated with dyspnea, depressed 
mood, and severity of reﬂux symptoms 
(36). In another study, scores on a sin-
gle-item sleep disruption scale were 
as high in Canadian SSc patients as 
those reported in rheumatoid arthritis 
patients, and higher than for the gener-
al population (37). Furthermore, pain 
was strongly associated with sleep 
disturbance. There is a need for more 
focused research on sleep problems in 
SSc. 
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Psychological distress/depression/
anxiety
Depressive symptoms are another prob-
lem in SSc. One study of a French co-
hort found that 1 in 5 SSc patients met 
criteria for a current episode of Major 
Depressive Disorder (MDD) (38). The 
range of patients who report depressive 
symptoms or distress based on self-re-
port questionnaires, which may or may 
not qualify as MDD, is understand-
ably higher (ranging from 36–65% of 
patients above recommended cut-offs) 
(39). Cross-sectional studies have re-
ported that sociodemographic factors 
(such as being unmarried and having 
lower education levels), disease vari-
ables (including overall disease sever-
ity, pain, more tender joints, breathing 
problems, and gastrointestinal func-
tioning), and psychological factors 
(e.g. body image distress, poor social 
support), are associated with greater 
distress symptomatology (39-41).
Few studies have examined anxiety 
among patients with SSc, and all have 
involved small sample sizes and self-
report questionnaires that assess levels 
of anxiety, but cannot determine the 
presence or absence of anxiety disor-
ders (42-44). One Dutch study (n=123) 
reported that fear of the future, includ-
ing the potential for uncontrolled and 
unpredictable disease progression, ma-
jor loss of function, inability to work, 
dependency on others, and mortality 
were among the top concerns reported 
by SSc patients (31). More research is 
needed to determine the extent of these 
fears and their impact on people living 
with SSc, as well as the presence of 
anxiety disorders, more generally and 
the association between anxiety and 
other common HRQoL dimensions, 
such as pain, sleep disturbance, and 
body image distress (13).  
Sexual dysfunction
The physical and psychological effects 
of SSc can lead to sexual dysfunction, 
including decreased desire and enjoy-
ment, impaired arousal, and painful sex 
(45). For instance, skin tightening and 
discomfort, shrinking of the mouth, joint 
pain, Raynaud’s phenomenon, gastroin-
testinal symptoms, vaginal tightness 
and dryness in women, and reduced 
penile blood ﬂow in men are physical 
consequences of SSc that can impede 
sexual functioning (46-48). Emotional 
distress and depressive symptoms, as 
well as concerns about physical appear-
ance, are psychological issues that may 
also impact sexual functioning among 
SSc patients. Although research in this 
area is limited, one study found that 
more than half of a sample of women 
with SSc reported impaired sexual 
function (47), and another reported that 
levels of sexual impairment in women 
with SSc are similar to or higher than 
levels for women with breast cancer, 
human immunodeﬁciency virus, or 
gynecologic cancer (49). Other factors 
associated with decreased sexual func-
tioning in SSc include vaginal discom-
fort and pain, fatigue, disease duration, 
and overall marital dissatisfaction (50).
Body image distress
Acquired disﬁgurement from an in-
jury or medical illness is often linked 
to problems with body image as well as 
social anxiety and avoidance (51). Ap-
pearance changes common in SSc often 
affect visible and socially relevant body 
parts, including the face and hands, and 
can potentially lead to challenges with 
social interactions. SSc patients have 
rated skin deformities as one of the 
most signiﬁcant stressors associated 
with the disease (31). Existing studies 
have shown that more severe disease 
manifestations, such as signiﬁcant skin 
changes in the hands, are associated 
with greater body image dissatisfaction, 
increased depressive symptoms, and re-
duced overall psychosocial functioning 
(31, 51, 52). 
The Scleroderma Patient-centred 
Intervention Network (SPIN)
Given the well documented extent of 
problems related to HRQoL in SSc, we 
believe that SSc researchers are ready 
to embark on interventional studies 
to develop a patient-centred care pro-
gramme for people with the disease. 
The ﬁrst step towards this end occurred 
in the fall of 2008 when a panel of inter-
nationally-recognised experts in behav-
ioural and psychological health in SSc, 
representatives from the Scleroderma 
Society of Canada, and Canadian Scle-
roderma Research Group researchers 
convened for a two-day meeting, fund-
ed by the Canadian Institutes of Health 
Research (CIHR). This meeting identi-
ﬁed important areas of concern for peo-
ple living with SSc related to HRQoL 
and developed a consensus research 
agenda, which was subsequently pub-
lished (13). In the fall of 2010, SPIN 
was conceived, and its initial meeting 
was held in Montreal, also with fund-
ing from the CIHR. This meeting built 
upon the 2008 meeting and was or-
ganised with the purpose of laying the 
groundwork to develop an investiga-
tive infrastructure for implementing a 
patient-centred care programme and 
testing interventions targeting the HR-
QoL of people living with SSc. Meet-
ing participants included researchers 
with expertise needed to develop and 
test patient-centred interventions fo-
cused on improving HRQoL in SSc; 
Canadian and international physician 
experts in SSc; and patient representa-
tives from the Scleroderma Society of 
Canada, Scleroderma Society of On-
tario, Sclérodermie Québec, the Sclero-
derma Foundation, and the Federation 
of European Scleroderma Associations 
(FESCA).
The core mission of SPIN is to develop 
and evaluate effective, feasible, eas-
ily accessible, cost-efﬁcient non-phar-
macological interventions for patients 
with SSc. Thus, SPIN’s patient-centred 
research programme will capitalise on 
technological approaches; and interven-
tions will be designed to be accessible 
via telecommunication such as instruc-
tional/downloadable videos, e-mail, in-
ternet or telephone, but will not require 
face-to-face contact with care provid-
ers, such as sessions with psychothera-
pists or customising splints and assis-
tive devices by physical or occupational 
therapists. SPIN will pilot each of the 
proposed interventions. Following this 
groundwork, the group will recruit pa-
tients through SPIN investigative centre 
sites and SPIN-afﬁliated patient organi-
sations for participation in RCTs.
There are many areas where SSc patients 
would potentially beneﬁt from accessi-
ble supportive care. As a ﬁrst step, SPIN 
members prioritised areas that have 
been identiﬁed by patients as having a 
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high impact on HRQoL and where there 
is enough basic research to conﬁdently 
develop and test an intervention in SSc. 
An additional consideration involved 
selecting intervention areas where there 
is a SSc-speciﬁc component that would 
not likely be addressed by interventions 
that are generally applied across disease 
groups. Thus, current SPIN priorities 
include the development and testing 
of interventions to improve hand func-
tion, reduce symptoms of psychological 
distress, address body image concerns 
related to signiﬁcant disﬁgurement, as 
well as to implement a general pro-
gramme for self-management geared to 
the needs of SSc patients.
A. Overview of SPIN approach 
and  research priorities
Innovations being proposed by SPIN 
that will facilitate the conduct of rigor-
ous testing and subsequent delivery of 
prioritised supportive care interventions 
include (1) the elaboration of an inter-
national collaborative network of ma-
jor SSc treatment and research centres 
and existing networks to conduct sup-
portive care intervention trials; (2) the 
use of the cutting-edge cohort multiple 
randomised controlled trial (cmRCT) 
design (53), which was developed spe-
ciﬁcally for pragmatic trials conducted 
to inform clinical practice in (i) open 
trials where treatment as usual is com-
pared with the offer of treatment, (ii) 
where rigorous blinding is not realistic, 
and (iii) where it is important to be able 
to conduct multiple trials; (3) capital-
ising on technological approaches in-
cluding downloadable videos, e-mail, 
internet and telephone; and (4) partner-
ing with patient organisations who, in 
collaboration with SPIN, will provide 
supportive care services to patients 
across a wide geographic range on an 
ongoing basis, following the initial de-
velopment and testing stage.
The cmRCT design (53) was devel-
oped to address some of the shortcom-
ings of pragmatic trial designs, which 
are highly relevant to SPIN, including 
recruitment difﬁculty inherent in the 
randomisation process for traditional 
RCTs; in nonpharmaceutical trials, the 
difﬁculty blinding patients and the “dis-
appointment bias” that can inﬂuence 
outcome reporting among patients who 
are not assigned to the intervention; 
and the ability to conduct only a single 
randomised trial in a group of recruited 
patients. In the cmRCT design, a large 
observational cohort is recruited and a 
set of core outcomes is regularly meas-
ured in these patients. Patients consent 
upon enrollment in the cohort to pro-
vide data that can be used to evaluate 
the beneﬁt of treatments for their con-
dition. For a given RCT conducted with 
the cohort, eligible patients are identi-
ﬁed, and a random selection of eligible 
patients is offered the trial intervention. 
Outcomes among patients who receive 
the intervention are then compared to 
outcomes among eligible patients who 
did not receive the intervention. Only 
patients who are offered the interven-
tion are notiﬁed and consented for the 
trial. An important feature of the cm-
RCT design is that enrollees can par-
ticipate in more than one study (though 
not at the same time) being conducted 
in the cohort, which is important given 
the difﬁculty recruiting patients with a 
rare disease, like SSc.
The ﬁrst priority of SPIN will be to 
develop a set of supportive care inter-
ventions. As this is occurring, we will 
begin to recruit the SPIN cohort, from 
which patients will be recruited for 
speciﬁc SPIN intervention trials. An 
important part of the SPIN program 
will be its focus on outcome measures. 
The SPIN Measurement Core will rely 
upon the OMERACT (Outcome Meas-
ures in Rheumatology) framework (54, 
55) to select the most appropriate out-
come measures for each intervention, 
prioritising measures that have met or 
are close to meeting OMERACT cri-
teria. An important task of the SPIN 
Measurement Core will be to use the 
cohort and included interventions to 
conduct further validation work on im-
portant patient-oriented outcome meas-
ures. The following sections describe 
interventions that have been prioritised 
for initial development by SPIN.
B. Physical/occupational therapy 
to improve hand function 
Several small RCTs have found that 
physical/occupational therapy inter-
ventions improve hand function in SSc 
(19). While the methods and outcome 
measures are reasonably well estab-
lished, there remains a major gap in 
the testing and implementation of in-
terventions that improve hand function, 
as well as appropriate care delivery. A 
Canadian Scleroderma Research Group 
needs survey identiﬁed that only 10% of 
Canadian patients with hand problems 
receive physical/occupational therapy 
(Bassel et al., under review). Patients 
often report that they cannot ﬁnd thera-
pists who are experienced in working 
with SSc or that they have had negative 
experiences with therapists unfamiliar 
with SSc. In order to address this, SPIN 
has prioritised a plan to develop and 
test a brief DVD/downloadable instruc-
tional video to educate physical/occu-
pational therapists on exercises unique 
to SSc to improve hand function for 
patients. Patients in need of a physical/
occupational therapist (PT/OT) will be 
able to share the instructional material 
with a PT/OT, which would support ac-
tive SSc patient management and help 
address a major need. A PT/OT, after a 
brief, 10-minute DVD/online training 
session, will be able to deliver more ef-
fective therapy. Planned outcomes will 
include improved overall hand function, 
as assessed by Cochin Hand Function 
Scale, as well as increased joint motion, 
grip strength, and grip pinch (19). Addi-
tionally, the McMaster-Toronto Arthri-
tis Patient Preference Disability Ques-
tionnaire (MACTAR) (56), a functional 
scale that includes patient priorities and 
has been used successfully in SSc (57), 
will be included as an outcome measure 
of the degree of difﬁculty experienced 
by patients when performing key activi-
ties of daily living. 
C. Telephone-based peer support 
to address psychological distress 
Peer support has been shown to be an 
effective ﬁrst step to reduce symptoms 
of depression and prevent MDD in 
a number of patient groups (58, 59). 
An RCT of telephone-based peer sup-
port (59) among postpartum women 
(n=701) reduced symptoms of depres-
sion by almost two-fold. In that study, 
trained community volunteers who had 
previously experienced and recovered 
from postpartum depression provided 
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telephone-based support. A similar ap-
proach would be well suited to SSc. 
Based on our preliminary work, it is 
clear that many people with SSc feel 
socially isolated and that they would 
beneﬁt from talking openly with some-
body who has experienced the prob-
lems they encounter. Although face-
to-face support groups for people with 
SSc who live in metropolitan areas ex-
ist, they are generally poorly attended 
and are largely inaccessible to patients 
in suburban or rural areas. A telephone- 
or internet-based support intervention 
would reduce barriers to attendance, 
such as difﬁculty travelling due to dis-
ability from SSc and would be avail-
able to patients who live far from urban 
centres. In addition, telephone-based 
support is ﬂexible, private, and non-
stigmatising. The planned primary out-
come will be symptoms of depression, 
as measured with the Patient Health 
Questionnaire-9 (PHQ-9), which has 
been validated for use in SSc (40).
D. Internet-based group support 
to reduce body image distress 
Social skills training programmes (e.g. 
60, 61) and cognitive-behavioural tech-
niques (62) have been recommended as 
strategies to reduce social avoidance re-
sulting from disﬁgurement and appear-
ance-related concerns among groups 
with acquired disﬁgurement. Changing 
Faces, a non-proﬁt organisation in the 
United Kingdom, has been a leader in 
developing workshop-based interven-
tions for persons with visible disﬁgure-
ment, with a focus on social skills train-
ing and cognitive behavioural therapy 
for social anxiety. Rigorous evidence 
of the effectiveness of these workshop-
based interventions is lacking. Howev-
er, there is some documentation of posi-
tive outcomes in terms of reduction of 
social avoidance, anxiety, and distress 
among disﬁgured individuals at post-
workshop follow-up (60). 
The content of these social skills train-
ing workshops are potentially applica-
ble to the appearance and body image 
concerns of people with SSc. The dis-
ﬁgurement experienced by many pa-
tients can be quite salient and is often 
found in visible and socially relevant 
body parts. 
As a result, anxiety about the social re-
actions of others and avoidance of social 
interactions may be an important issue 
for many SSc patients. Given this, the 
content and strategies incorporated in 
the social skills training workshops will 
serve as the foundation for the develop-
ment of a workshop-based intervention 
that we plan to adapt for easy delivery 
to SSc patients with signiﬁcant body 
image concerns, via either telephone 
or internet. The method of delivery of 
these workshops will depend largely 
on the comfort levels of the patients, 
as video-based interactions may not be 
appealing to individuals with concerns 
about their physical appearance. The 
Brief-Satisfaction with Appearance 
Scale, which has been adapted and vali-
dated for SSc, (63) and which measures 
appraisal of appearance and comfort in 
social interactions, will be used as the 
primary outcome measure.
E. Internet-based self-management 
for scleroderma 
Effective management of chronic ill-
ness places extensive day-to-day de-
mands on patients and their caregiv-
ers. Patients must adhere to medication 
and other medical recommendations, 
make signiﬁcant lifestyle and behav-
ioural changes, and learn to cope with 
psychological and social issues in-
herent to living with a chronic illness 
(64, 65). As a result, and because of 
recognition of the beneﬁts that are ac-
crued when patients increase personal 
control in health matters, patient self-
management programmes have been 
increasingly emphasised. The Chronic 
Disease Self-Management Programme 
(CDSMP), which was developed by 
Kate Lorig and modeled on her Arthri-
tis Self-Management Programme, is 
designed to teach self-care techniques 
useful to persons with various chronic 
diseases (66). The CDSMP has been 
widely adapted, and an internet-based 
version of the programme improved 
self-efﬁcacy and overall health status in 
a RCT that included patients with heart 
disease, lung disease, and type II dia-
betes (66). Although the program is de-
signed for general use by patients with 
chronic diseases, in focus groups con-
ducted by the Canadian Scleroderma 
Research Group, patients with SSc in-
dicated that they would be more likely 
to ﬁnd the programme beneﬁcial if top-
ics were geared towards managing the 
unique demands of living with SSc (e.g. 
skin care strategies, strategies to over-
come eating difﬁculties and tempera-
ture changes) and if other participants 
in the workshops also had SSc. Prelimi-
nary work has been conducted to deter-
mine how best to adapt the CDSMP to 
meet the needs of patients with SSc, as 
well as how best to adapt the technol-
ogy platform for a SSc-focused pro-
gramme. Trials of CDSMP typically 
measure self-efﬁcacy, as well as more 
standard outcomes (e.g. pain, fatigue) 
and the best outcomes to measure in a 
group of SSc patients with a diverse set 
of problems will be an important part of 
the project development stage.
Conclusions
Numerous sources of evidence high-
light the negative effects of SSc on HR-
QoL; however, no rigorous trials have 
been conducted to examine treatment 
strategies and no recommendations 
have been made regarding interven-
tion approaches. One of the primary 
reasons that SPIN has been created is 
to provide a network of experts to ﬁll 
the gap in SSc psychosocial and allied 
health research and clinical practice, by 
developing and testing patient-centred 
interventions with the goal of broad 
dissemination of evidence-based inter-
ventions for use by a spectrum of peo-
ple with the disease as well as provid-
ers that care for these patients. Ideally, 
in the long-term, interventions devel-
oped and tested by SPIN will be incor-
porated into a menu of options to ad-
dress the diverse problems experienced 
by people living with SSc, which can 
be made available through outlets, such 
as the websites of patient organisations 
across the globe.
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